crizotinib Mar 23, 2022 Xcovery's Ensartinib Approved for First-Line ALK-Positive NSCLC in China Mar 18, 2022 In Brief This Week: Ideaya Biosciences, Pfizer, Strata Oncology, Qualigen Therapeutics Feb 8, 2022 Pfizer Q4 Oncology Revenues Grow Seven Percent Despite Ibrance, Xalkori Slowdowns Jul 28, 2021 Pfizer Nearly Doubles Q2 Revenues Jan 28, 2021 Pfizer, Celcuity Partner on Phase II Breast Cancer Trial of Vizimpro, Xalkori Jan 15, 2021 FDA Approves Pfizer's Xalkori for Pediatric ALK-Positive Lymphoma Jan 5, 2021 Ideaya Biosciences Begins Trial of IDE196, Xalkori in Uveal Melanoma Patients Sep 24, 2020 Ideaya, Pfizer Expand Collaboration to Study IDE196, Xalkori Sep 23, 2020 FDA Accepts Pfizer's sNDA for Xalkori in Rare ALK-Positive Pediatric Leukemia Indication Sep 20, 2020 Pfizer's Lorbrena Yields Impressive Responses in ALK-Positive NSCLC With Brain Metastases Premium Sep 14, 2020 COVID-19 Experience Spurs Cancer Research Community to Embrace Telemedicine-Enabled Trials Aug 18, 2020 NCI SEER Registry Data Analysis Suggests Precision Medicine's Role in Fewer NSCLC Deaths Premium Aug 10, 2020 Xcovery's Ensartinib Extends PFS in First-Line Advanced ALK-Positive NSCLC Jun 20, 2018 Merck KGaA Advancing Tepotinib in MET-Altered Cancer Subpopulations Premium May 24, 2018 Lung Cancer Study Investigates Role of Protein Modifications in Cell Signaling, Drug Response Premium Aug 15, 2017 ASCO Updates NSCLC Guidelines With New Directives for Genomic Testing Breaking News In Brief This Week: Gilead Sciences, Arcus Biosciences, Verismo Therapeutics, Caris Life Sciences Pyxis Oncology Gets FDA Permission to Start Phase I Trials of Anti-EDB Drug, Immunotherapy FDA Approves Rigel Pharmaceuticals' Rezlidhia for IDH1-Mutant AML Sofie Biosciences to Begin Trial of Fluorine-Labeled PET Diagnostic Imaging Agent for GI Cancers Study Unearths Features Found in Long-Term Survivors of Advanced Ovarian Cancer Carrick Therapeutics Receives $35M Investment From Pfizer; Raises $25M in Series C Funding Round
